檢索結果 - Gary Meininger

Refine Results
  1. 1
    Renal effects of canagliflozin in type 2 diabetes mellitus

    Renal effects of canagliflozin in type 2 diabetes mellitus 由 Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar, Gary Meininger

    出版 2015
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

    Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program 由 Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

    Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin A... 由 B Charbonnel, Avraham Karasik, Ji Liu, Mei Wu, Gary Meininger

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

    Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus 由 Melanie J. Davies, A. Trujillo, Ujjwala Vijapurkar, C. V. Damaraju, Gary Meininger

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

    Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on met... 由 Michael A. Nauck, Gary Meininger, Pei Chia Eng, Lisa Terranella, Peter P. Stein

    出版 2007
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

    Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone 由 Thomas Först, Robert Guthrie, Ronald Goldenberg, Jacqueline Yee, Ujjwala Vijapurkar, Gary Meininger, Peter Stein

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

    Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects 由 Hiddo J.L. Heerspink, Mehul Desai, Meg Jardine, Dainius Balis, Gary Meininger, Vlado Perkovic

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Reliability and Feasibility of Methods to Quantitatively Assess Peripheral Edema

    Reliability and Feasibility of Methods to Quantitatively Assess Peripheral Edema 由 K. Brodovicz, Kristin S. McNaughton, Naoto Uemura, Gary Meininger, Cynthia J. Girman, Steven H. Yale

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus

    Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus 由 Matthew R. Weir, Andrzej Januszewicz, Richard E. Gilbert, Ujjwala Vijapurkar, Irina Kline, Albert Fung, Gary Meininger

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

    Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus 由 Nelson B. Watts, John P. Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

    Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise 由 Kaj Stenlöf, William T. Cefalu, Kyung‐Ah Kim, Maria Alba, Keith Usiskin, C. Tong, William Canovatchel, Gary Meininger

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus

    Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus 由 John Wilding, Lawrence Blonde, Lawrence A. Leiter, Sonia Cerdas, Cindy S.W. Tong, Jacqueline Yee, Gary Meininger

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

    Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial 由 Fernando J. Lavalle‐González, Andrzej Januszewicz, Jaime A. Davidson, C. Tong, R. Qiu, William Canovatchel, Gary Meininger

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis

    Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis 由 Alan J. Sinclair, Bruce W. Bode, Stewart B. Harris, Ujjwala Vijapurkar, Wayne Shaw, Mehul Desai, Gary Meininger

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515

    Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Di... 由 Guntram Schernthaner, JL Gross, J Rosenstock, M Guarisco, Minghuan Fu, Jacqueline Yee, Mayuko Kawaguchi, William Canovatchel, Gary Meininger

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

    Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea 由 Guntram Schernthaner, Jorge Luiz Gross, Julio Rosenstock, M Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study

    Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M stud... 由 Kaj Stenlöf, William T. Cefalu, Kyoung‐Ah Kim, Esteban Jódar, Maria Alba, Robert Edwards, Cindy S.W. Tong, William Canovatchel, Gary Meininger

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

    Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes 由 Gary Meininger, Russell Scott, Maria Alba, Yue Shentu, Edmund Luo, Himal Amin, Michael J. Davies, Keith D. Kaufman, Barry J. Goldstein

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

    Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double... 由 Lawrence A. Leiter, Kun‐Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius Balis, Dawn Millington, Frank Vercruysse, William Canovatchel, Gary Meininger

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

    Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies 由 Alan J. Sinclair, Bruce W. Bode, Stewart B. Harris, Ujjwala Vijapurkar, Cristiana Mayer, Albert Fung, Wayne Shaw, Keith Usiskin, Mehul Desai, Gary Meininger

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: